Physician profile
Ross L Guarino
NPI 1487703898
$12,909.68
in general payments reported to CMS, 2019-2025
62 companies · $1,621 in 2025
The $1,621 reported for 2025 was more than what 94% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,611 · 2022: $4,008 · 2023: $1,845 · 2024: $1,825 · 2025: $1,621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,291.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,728.12 | 2021-2025 | Octrode, Ionicrf |
| Collegium Pharmaceutical, INC. | $1,180.95 | 2021-2025 | Belbuca, Xtampza |
| Boston Scientific Corporation | $1,153.40 | 2021-2025 | Wavewriter Alpha Prime 16 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $838.84 | 2021-2025 | Relistor |
| Vanda Pharmaceuticals INC. | $737.18 | 2021-2024 | Hetlioz |
| Amgen INC. | $565.79 | 2021-2022 | |
| Nevro Corp. | $559.95 | 2021-2022 | |
| Abbvie INC. | $539.84 | 2021-2024 | |
| Curonix LLC | $493.99 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Biohaven Pharmaceuticals, INC. | $348.62 | 2021 | |
| Spr Therapeutics, INC | $337.68 | 2023-2025 | Sprint Pns System |
| Protega Pharmaceutials INC | $305.23 | 2024-2025 | Roxybond |
| Biohaven Pharmaceutical Holding Company LTD. | $278.53 | 2022 | |
| Pfizer INC. | $215.65 | 2025 | |
| Biogen, INC. | $196.58 | 2023 | Vumerity |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ross Guarino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.